Ahmedabad: Intas Pharmaceuticals has appointed Nitin Patel as Associate Vice President - Global Portfolio, Project & Business Development and Dr Rupesh Rane has also been named as Associate Vice President – International Business at Intas Animal Health.
Nitin brings deep expertise in project and lifecycle management, licensing and contracting, mergers and acquisitions, portfolio strategy, deal execution, and business development. Prior to joining Intas, he held roles at Thermo Fisher Scientific, Cadila Healthcare, and Claris.
"We look forward to his contributions as we continue to strengthen our global presence and uphold our purpose of creating an expression for a healthy life," Intas stated in a Linkedin post announcing Nitin appointment.
Dr. Rupesh Rane joins with over 25 years of rich industry experience across diverse segments including cattle, poultry, canine, equine, and aquaculture.
He has previously worked with leading companies such as Piramal Enterprises, Lyka Labs, Zenex Animal Health, and Alivira Animal Health. His deep understanding of international markets, coupled with proven expertise in business development, product innovation, client engagement, and strategic sales, makes him a valuable addition to Intas team.
Sharing his enthusiasm, Dr Rane commented, "Thrilled to join Intas Animal Health, where I aim to strengthen international business and deliver meaningful growth across diverse species and geographies."
Nitin Patel also expressed his excitement, saying, "I'm excited to join Intas and contribute to building a high-impact global portfolio through strategic innovation, collaboration, and seamless project execution."
Intas is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.